PARIS — EOS imaging (Euronext Paris, FR0011191766 - EOSI), the pioneer in orthopedic 2D/3D imaging, announced today that usage of its customized, 3D-printed surgical cutting blocks has begun for knee surgeries in Australia. The patient specific cutting blocks, developed and manufactured by EOS imaging subsidiary OneFit Medical, had been until now used for surgeries in seven European countries.

The 3D cutting blocks engineered by OneFit Medical are designed to

match the individual patient's anatomy to help surgeons perform fast,

precise knee replacement surgeries. OneFit Medical's cutting blocks are

currently developed using MRI and CT images and sold to implant

manufacturers, within agreements that include today 20 implant

manufacturers. The Company is exploring the development of improved

instruments utilizing EOS images.

EOS imaging and OneFit Medical are developing additional EOS-based

solutions, such as hipEOS which was granted CE mark last March for hip

replacement surgery. hipEOS, the first offering of a software portfolio

associated with the EOS imaging system, will be deployed later this

year in Europe as an online service to assist surgeons in hip

prosthesis selection and placement simulation based on 3D images

generated by the EOS system.

Marie Meynadier, CEO of EOS imaging, said, "Building on robust

international sales of our EOS imaging system, the consumable product

offerings generated by OneFit will provide an additional revenue stream

for the Company besides equipment purchases and service fees. We look

forward to expanding our OneFit technology with hipEOS software and

other future applications."

For more information, please visit www.eos-imaging.com.

About EOS imaging:

EOS imaging designs, develops, and markets EOS(R), a patented medical

imaging system based on technology that enabled George Charpak to win

the Nobel Prize for Physics. The Company is authorized to market the

system in 32 countries, including the United States (FDA), Japan,

Canada, Australia and the European Union (EU). Backed by an installed

base of more than 10 sites and more than 400,000 imaging sessions,

EOS(R) benefits from worldwide recognition within the global medical

community. As of December 31, 2013 the Group posted 2013 consolidated

revenue of [Eur]15.2 million and employed 101 people including an R&D

team of 38 engineers. The Group is based in Paris and holds four

subsidiaries in Besancon (France), Cambridge (Massachusetts), in

Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.

For further information, please visit www.eos-imaging.com